Clearside Biomedical - CLSD Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1-year price targets for Clearside Biomedical's shares. Their CLSD share price forecasts range from $4.00 to $8.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 527.0% from the stock's current price.
View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts.

Clearside Biomedical's stock was trading at $1.12 at the beginning of 2023. Since then, CLSD stock has decreased by 14.6% and is now trading at $0.9570.
View the best growth stocks for 2023 here.

Clearside Biomedical saw a increase in short interest in March. As of March 15th, there was short interest totaling 351,200 shares, an increase of 8.7% from the February 28th total of 323,100 shares. Based on an average trading volume of 237,900 shares, the short-interest ratio is presently 1.5 days. Currently, 0.7% of the company's stock are sold short.
View Clearside Biomedical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our CLSD earnings forecast.

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm earned $3.07 million during the quarter, compared to the consensus estimate of $3.32 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 153.06% and a negative net margin of 2,482.82%. During the same quarter in the previous year, the business earned ($0.05) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.98%), Johnson & Johnson (0.28%), Assenagon Asset Management S.A. (0.28%), Two Sigma Investments LP (0.17%), Northeast Financial Consultants Inc (0.14%) and Hamilton Lane Advisors LLC (0.11%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends.

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSD stock can currently be purchased for approximately $0.96.

Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $58.72 million and generates $1.33 million in revenue each year. The company earns $-32,950,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.